Compare AST SpaceMobile Inc (ASTS) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AST SpaceMobile Inc vs BioNano Genomics Inc — how do they compare? AST SpaceMobile Inc trades at $71.94 (market cap $20.54B), while BioNano Genomics Inc trades at $1.18 (market cap $13.31M). The key difference: AST SpaceMobile Inc is far larger — about 1543.2× BioNano Genomics Inc's market cap, and AST SpaceMobile Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| ASTS | BNGO | |
|---|---|---|
Market Cap | $20.54B | $13.31M |
Sector | Media | Health |
52-Week High | $133.09 | $4.92 |
52-Week Low | $36.91 | $1.06 |
Enterprise Value | $21.25B | $15.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AST SpaceMobile (ASTS) trades at $71.94, up 6.8% on the day, reflecting strong momentum despite recent earnings misses. The stock shows a bullish technical signal with key resistance at $73 and support at $69. Fundamentally, revenue grew to $71M in 2025, but net losses persist at -$342M, with a negative net margin of -482.17%. The company maintains a $1.3B backlog and raised its 2026 revenue guidance to $150M-$200M, indicating growth potential amid high cash burn.
Outlook: ASTS offers speculative upside driven by satellite network expansion and partnerships, with a consensus price target of $85.45 (19% upside). Risks include sustained losses, execution delays, and high valuation (P/S of 230.94). Investors should weigh growth prospects against financial sustainability concerns.
BNGO trades at $1.16, up 5.45% today, with a bullish technical signal from moving averages. The company shows improving financial trends with revenue stabilizing around $29M annually and narrowing losses from -$232M in 2023 to -$26M in 2025. Recent earnings beats and positive news flow around optical genome mapping adoption support momentum.
While BNGO demonstrates operational improvement and analyst support (57% buy ratings), the stock faces significant risks including persistent negative profitability, cash burn requiring ongoing financing, and competitive pressures in genomic technology. The current valuation appears attractive on P/S and P/B metrics but reflects the company's pre-profitability stage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
